Abstract:The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), was first identified in Eastern Asia (Wuhan, China) in December 2019. The virus then spread to Europe and across all continents where it has led to higher mortality and morbidity, and was declared as a pandemic by the World Health Organization (WHO) in March 2020. Recently, different vaccines have been produced and seem to be more or less effective in protecting from COVID-19. The renin–angiotensin system (RAS), an essential enzymatic cascade involved in maintaining blood pressure and electrolyte balance, is involved in the pathogenicity of COVID-19, since the angiotensin-converting enzyme II (ACE2) acts as the cellular receptor for SARS-CoV-2 in many human tissues and organs. In fact, the viral entrance promotes a downregulation of ACE2 followed by RAS balance dysregulation and an overactivation of the angiotensin II (Ang II)–angiotensin II type I receptor (AT1R) axis, which is characterized by a strong vasoconstriction and the induction of the profibrotic, proapoptotic and proinflammatory signalizations in the lungs and other organs. This mechanism features a massive cytokine storm, hypercoagulation, an acute respiratory distress syndrome (ARDS) and subsequent multiple organ damage. While all individuals are vulnerable to SARS-CoV-2, the disease outcome and severity differ among people and countries and depend on a dual interaction between the virus and the affected host. Many studies have already pointed out the importance of host genetic polymorphisms (especially in the RAS) as well as other related factors such age, gender, lifestyle and habits and underlying pathologies or comorbidities (diabetes and cardiovascular diseases) that could render individuals at higher risk of infection and pathogenicity. In this review, we explore the correlation between all these risk factors as well as how and why they could account for severe post-COVID-19 complications.

COVID-19 and Microvascular Disease: Pathophysiology of SARS-CoV-2 Infection With Focus on the Renin-Angiotensin System

The mechanism of multiple organ dysfunction syndrome in patients with COVID-19

The Mechanism of Multiple Organ Dysfunction Syndrome in Patients with COVID‐19

Cardio-Pulmonary-Renal Consequences of Severe COVID-19

The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19

The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19.

Vascular Manifestations of COVID-19 – Thromboembolism and Microvascular Dysfunction

Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19

Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review

Viral Endothelial Dysfunction: A Unifying Mechanism for COVID-19

SARS-CoV-2 and coagulation disorders in different organs

Endothelial cells and SARS-CoV-2: An intimate relationship

COVID-19 and the cardiovascular system: a study of pathophysiology and interpopulation variability

Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review

Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research Practices

New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic

Role of SARS-COV-2 and ACE2 in the pathophysiology of peripheral vascular diseases

Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies